Molecular Diagnosis & Prognosis of Severe Pulmonary Infection

Status Not yet recruiting

Clinical Trial Summary

Serious pneumonia is a serious inflammation of the lungs caused by various pathogens, resulting in severe bacteraemia or toxemia, which in turn causes blood pressure drop, shock, blurred consciousness, restlessness, delirium and coma, etc., and requires intensive care and treatment in intensive care unit (ICU) because of its seriousness. There is an upward trend in the number of clinically immunosuppressed host patients, including long-term use of glucocorticoids for rheumatoid immune diseases and kidney diseases, tumor chemotherapy, organ transplantation, etc. A huge risk for these patients is the diagnosis and treatment of infections, especially lung infections. We have previously observed a significant increase in mortality from severe pneumonia in immunosuppressed patients, and our recent analysis of 204 patients with novel coronavirus pneumonia found that low lymphatic counts, immunosuppression, etc. were independent risk factors for death in patients. Early diagnosis and timely treatment are the main means to reduce the mortality rate of severe pneumonia. CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate the downstream action of all three complement activation pathways, and CD55 protects host cells from complement attack. Our previous study found that CD55 was significantly elevated in patients with severe pneumonia. Therefore, this project proposes "Early diagnosis of severe pneumonia based on combination of biomarkers with new generation pathogenesis and early clinical manifestations". It is proposed to validate the predictive effects of recently discovered markers such as CD55, HBP and CD64 on severe pneumonia through prospective single-center clinical studies, explore the establishment of new predictive models for early diagnosis of severe pneumonia, and optimize the diagnosis and treatment strategy of severe pneumonia, and provide new ideas for accurate treatment of severe pneumonia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04395066
Study type	Observational [Patient Registry]
Source	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status	Not yet recruiting
Phase
Start date	June 1, 2020
Completion date	June 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05845112` - Start Taking Action For TB Diagnosis
Not yet recruiting	`NCT05889312` - Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
Completed	`NCT01194557` - Introducing Rapid Diagnostic Tests Into the Private Health Sector	N/A
Completed	`NCT04257955` - COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer
Recruiting	`NCT05698212` - Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers	Phase 2
Recruiting	`NCT03372330` - Peripheral Artery Disease and Sepsis Outcomes	N/A
Active, not recruiting	`NCT06134011` - A Multi-omics-based Metabolic Typing Study of Gastric Cancer
Recruiting	`NCT06289803` - The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery	N/A
Not yet recruiting	`NCT06025240` - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Not yet recruiting	`NCT05464576` - Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis	N/A
Completed	`NCT06185127` - Dexmedetomidine-ketamine Combination Versus Fentanyl-midazolam During Bronchoscopy	Phase 3
Recruiting	`NCT05824442` - Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis	N/A
Not yet recruiting	`NCT06072820` - Analytical Evaluation of the Endotest® Diagnostic	N/A
Recruiting	`NCT05587114` - Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood
Recruiting	`NCT06230458` - Fractional Exhaled Nitric Oxide (FeNO)- Test as add-on Test in the Diagnostic Work-up of Asthma	N/A
Not yet recruiting	`NCT05948410` - How Does the Mood of the Patients Change Before and After the Invasive Urodynamic Study?
Not yet recruiting	`NCT05947565` - Patient Position and Invasive Urodynamic Study Results in Males	N/A
Not yet recruiting	`NCT04490746` - Identifcation of Biomarkers for Active Pulmonary Tuberculosis
Completed	`NCT03381131` - Chinese Version of Fibromyalgia Criteria and Severity Scales Study
Recruiting	`NCT05992519` - Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Molecular Diagnosis and Prognosis of Severe Pulmonary Infection Immunosuppressed Hosts

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms